Sopharma AD-SofiaFRA:3JR +6.36%65 PB Ratio is 1.86 as of Jul. 04, 2026, which is 2% above its 10-year median of 1.83. GuruFocus rates FRA:3JR with a GF Score™ of 65/100 and a GF Value™ of €3.02 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 110 Medical Distribution companies, Sopharma AD-Sofia ranks worse than 67.27% on this metric.
The historical rank and industry rank for Sopharma AD-Sofia's PB Ratio or its related term are showing as below:
FRA:3JR'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 1.83 Max: 3.04
Current: 1.94
During the past 13 years, Sopharma AD-Sofia's highest PB Ratio was 3.04. The lowest was 0.91. And the median was 1.83.
FRA:3JR's PB Ratio is ranked worse than 67.27% of 110
companies
in the Medical Distribution industry
Industry Median: 1.02
vs FRA:3JR: 1.94
During the past 12 months, Sopharma AD-Sofia's average Book Value Per Share Growth Rate was -62.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -13.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 0.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Sopharma AD-Sofia was 12.10% per year. The lowest was -32.20% per year. And the median was 6.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sopharma AD-Sofia PB Ratio Related Terms
Sopharma AD-Sofia PB Ratio Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sopharma AD-Sofia (FRA:3JR) has a PB Ratio of 1.86 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sopharma AD-Sofia and its competitors. This is near median its historical median of 1.83. Over the past decade, Sopharma AD-Sofia's PB Ratio has ranged from 0.91 to 3.04. According to the industry distribution chart, Sopharma AD-Sofia ranks #74 out of 110 companies in the Medical Distribution industry, placing it in the top 67.3%.
Is Sopharma AD-Sofia's PB Ratio too high?
Sopharma AD-Sofia's current PB Ratio of 1.86 is near median its 10-year median of 1.83. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 3.04. The Medical Distribution industry median PB Ratio is 1.02. Sopharma AD-Sofia's value of 1.86 is 82.4% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #74 out of 110 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Sopharma AD-Sofia has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's PB Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #74 out of 110 companies for PB Ratio. This places Sopharma AD-Sofia in the lower half of its industry. The industry median PB Ratio is 1.02. Sopharma AD-Sofia's value of 1.86 is 82.4% above this benchmark. Historically, Sopharma AD-Sofia's own PB Ratio has ranged from 0.91 to 3.04 over the past decade. While the company's 10-year median is 1.83 vs. the industry median of 1.02, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.02, based on 110 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current PB Ratio of 1.86 is 82.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current PB Ratio is 1.86, which is near median its own 10-year median of 1.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (FRA:3JR) is currently considered Possible Value Trap. The stock's GF Value™ is €3.02, compared to a current price of €1.84 — trading 39.1% below its estimated fair value. The current PB Ratio is 1.86, which is near median its 10-year median of 1.83 and 82.4% above the Medical Distribution industry median of 1.02. Sopharma AD-Sofia's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sopharma AD-Sofia (FRA:3JR), the current PB Ratio is 1.86 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (FRA:3JR) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of €1.84 is trading 39.1% below its estimated GF Value™ of €3.02.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for FRA:3JR:
PB Ratio: 1.86 (near median its 10-year median of 1.83)
GF Value™: €3.02 vs. price of €1.84 (39.1% below fair value)
Industry Position: 82.4% above the Medical Distribution median (#74 of 110)
No single metric tells the full story. See the FRA:3JR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
65GF Score
Get the complete analysis for FRA:3JR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3JR has been successfully added to your 
